Diagnosis

Peritoneal carcinomatosis often spreads across the abdominal lining without forming distinct masses. Because of this, doctors usually need to combine imaging, fluid tests, and sometimes surgery, to confirm a diagnosis.

Tests

  • Imaging tests. Imaging tests such as CT, MRI and PET scans are typically the first step in looking for suspected peritoneal carcinomatosis. These scans help identify visible tumor spread, fluid buildup or organ involvement. However, imaging is often not sensitive enough to detect smaller cancers or early peritoneal disease. Therefore, a negative scan does not rule out peritoneal carcinomatosis.
  • Peritoneal washing cytology. In this test, fluid from the abdominal cavity is surgically collected during a minor procedure. It's then examined under a microscope. Healthcare professionals use peritoneal washing cytology to check for cancer cells floating in the peritoneal fluid. Even when no visible cancer is present, a positive cytology result is a strong sign that peritoneal spread has happened.
  • Staging laparoscopy. Staging laparoscopy is a safe, minimally invasive surgical procedure used to look directly inside the abdominal cavity using a small camera. It allows healthcare professionals to inspect the peritoneum, find hidden tumors, and take tissue or fluid samples. This test is especially valuable for finding peritoneal metastases that are too small to be seen with imaging.
  • Tumor marker tests. Tumor marker tests use a sample of blood to look for chemicals made by cancer cells.
  • Circulating tumor DNA (ctDNA). This is a newer blood test that looks for small pieces of DNA from cancer cells in the blood. It can help find peritoneal cancer that doesn't show up on scans. However, the role of ctDNA in diagnosis is still uncertain.
July 03, 2025
  1. Gastric cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1434. Accessed May 13, 2025.
  2. National Cancer Institute. Peritoneal carcinomatosis. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/peritoneal-carcinomatosis. Accessed May 13, 2025.
  3. Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ipg688. Accessed May 13, 2025.
  4. DeVita VT Jr, et al., eds. Peritoneal metastases and peritoneal mesothelioma. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. ProQuest Ebook Central. Wolters Kluwer; 2023. Accessed May 13, 2025.
  5. Lewis KA, et al. Educational review: Updates on therapeutic strategies for gastric cancer with peritoneal metastasis. Annals of Surgical Oncology. 2025; doi:10.1245/s10434-025-17069-3.
  6. Sigler GI, et al. Diagnostic advances and novel therapeutics in peritoneal metastasis. Surgical Oncology Clinics of North America. 2025; doi:10.1016/j.soc.2024.12.005.
  7. Blaj S, et al. Peritoneal carcinomatosis in colorectal cancer: Review and update of current clinical data. Clinical Colorectal Cancer. 2024; doi:10.1016/j.clcc.2024.05.007.
  8. Acs M, et al. Peritoneal metastatic gastric cancer: Local treatment options and recommendations. Current Oncology. 2024; doi:10.3390/curroncol31030109.
  9. Foster JM, et al. The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future. CA: A Cancer Journal for Clinicians. 2023; doi:10.3322/caac.21749.
  10. Werba G, et al. Treatment and management of peritoneal spread from colorectal cancer peritoneal metastasis. Surgical Oncology Clinics of North America. 2025; doi:10.1016/j.soc.2024.11.001.
  11. Pozzar RA, et al. Experiences of patients with peritoneal carcinomatosis-related complex care needs and their caregivers. Gynecology Oncology. 2024; doi:10.1016/j.ygyno.2023.12.013.
  12. Huang B, et al. Gastric and gastroesophageal junction cancer: Risk factors and prophylactic treatments for prevention of peritoneal recurrence after curative intent surgery. Annals of Gastroenterological Surgery. 2021; doi:10.1002/ags3.12565.
  13. Li Z, et al. Predicting peritoneal carcinomatosis of gastric cancer: A simple model to exempt low-risk patients from unnecessary staging laparoscopy. Frontiers in Surgery. 2022; doi:10.3389/fsurg.2022.916001.
  14. Goldman L, et al., eds. Inflammatory and anatomic diseases of the intestine, peritoneum, mesentery, and omentum. In: Goldman-Cecil Medicine. 27th ed. Elsevier; 2024. https://www.clinicalkey.com. Accessed June 13, 2025.
  15. Vallejo JS, et al. Assessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Revista do Colégio Brasileiro de Cirurgiões. 2023; doi:10.1590/0100-6991e-20233421-en.
  16. Harris KM. Allscripts EPSi. Mayo Clinic. June 12, 2025.
  17. Ferri FF. Ascites. In: Ferri's Clinical Advisor 2025. Elsevier; 2025. https://www.clinicalkey.com. Accessed June 13, 2025.
  18. Hoskins MA, et al. Data-driven surveillance protocol for patients at risk for peritoneal recurrence of primary colon cancer: Surveillance for peritoneal carcinomatosis. Journal of Clinical Medicine. 2024; doi:10.3390/jcm13082358.
  19. Zhang Y, et al. Risk factors for synchronous peritoneal metastases in colorectal cancer: A systematic review and meta-analysis. Frontiers in Oncology. 2022; doi:10.3389/fonc.2022.885504.
  20. Medical review (expert opinion). Mayo Clinic. June 13, 2025.